Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Inhibits human aldosterone synthase, reducing aldosterone production and plasma aldosterone concentrations. This reduces renal sodium and water retention and lowers blood pressure; baxdrostat is more potent and selective for aldosterone synthase than the related cortisol-synthesis enzyme 11β-hydroxylase.
Indications / reported uses
Treatment of hypertension in adults who are not adequately controlled on other agents, in combination with other antihypertensive drugs, under the US FDA BAXFENDY indication (initial US approval 2026)
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Baxdrostat PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Baxdrostat Permitted Daily Exposure (PDE) report (the Baxdrostat PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Baxdrostat Occupational Exposure Limit (OEL) report (the Baxdrostat OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.